AMRI makes a promotion in Singapore

Takeshi Yura becomes senior director of drug discovery services

Takeshi Yura has been promoted to senior director of drug discovery services at AMRI’s Singapore subsidiary.

In this expanded role, Yura will take overall responsibility for site management, which includes leadership of the AMRI Singapore Research Centre's chemistry, biology and r&d operations.

Yura will replace Raymond Yeung, who has been managing director of the site from 2007.

Initially joining the Singapore subsidiary in January as assistant director of medicinal chemistry, Yura has more than 22 years of experience in discovery chemistry, project management and business development.

Prior to joining AMRI, he was a director at Dishman Japan, responsible for sales and business development activities. Before this he was discovery chemistry research head at Pfizer Japan, and section head of medicinal chemistry at Bayer Yakuhin.

‘Since joining us earlier this year, we have been impressed with the extent of scientific and business leadership Dr Yura has brought to AMRI and look forward to the additional contributions he will bring to the company in this new role,’ said Bruce Sargent, senior vp of drug discovery at AMRI.

You may also like

Manufacturing

25 years of Guardtech: Isopod Manufacturing Director Michael Burton Q&A

One of the Group’s longest-serving superstars gives his thoughts on why the Guardtech Group are pushing the boundaries of small-scale cleanroom provision with their rapid-assembly pod systems
Research & Development

Genentech provides update on Astegolimab in chronic obstructive pulmonary disease

Pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every 2 weeks
Manufacturing

Aenova expands Killorglin site with spray drying platform

New equipment to help overcome bioavailability hurdles and accelerate time-to-market
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Precision under pressure

Why pharma manufacturing needs a harder look at weight control
Research & Development

Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies
Subscribe now